To investigate whether the EGFR inhibitor gefitinib could increase the antitumor effect of DXR against the adrenal tumors of transgenic mice, we evaluated the antitumor activity of gefitinib alone and in combination with unencapsulated or liposomal DXR. Here, EGFR is linked to adrenal gland neoplasm.